Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.77 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.55 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.55 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.55 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16670 | 1.00 | HSD11B1 (0.77) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL15979 | 1.00 | HSD11B1 (0.77) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL13239422 | 0.90 | HSD11B1 (0.71) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL13239437 | 0.89 | HSD11B1 (0.79) | HSD11B1 | |
| SCHEMBL13239441 | 0.87 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL16281 | 0.85 | HSD11B1 (0.61) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL16736 | 0.85 | HSD11B1 (0.61) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL12078980 | 0.85 | HSD11B1 (0.61) | HSD11B1ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL12093430 | 0.85 | HSD11B1 (0.68) | HSD11B1 | |
| SCHEMBL12093382 | 0.85 | HSD11B1 (0.68) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | HSD11B1 1443/4885ABCC9 862/4885ABCC8 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.